Another AZ exec jumps ship for CEO job at smaller drugmaker

AstraZeneca ($AZN) has lost its second top executive in less than two weeks, as VP James Ward-Lilley bids goodbye to Big Pharma to run the respiratory specialist Vectura--which happens to have partnerships with AZ lung-drug rivals GlaxoSmithKline ($GSK) and Novartis ($NVS). Currently head of AZ's portfolio strategy in respiratory, inflammation and autoimmunity, Ward-Lilley will join Vectura Oct. 1. Story | Release

Suggested Articles

Imbruvica has enjoyed a nice run in previously untreated CLL over the last few years. But major competition is here in the form of AZ's Calquence.

In the asthma biologics race, there doesn't appear to be a clear favorite among Xolair, Dupixent, Fasenra and Nucala for a group of pulmonologists.

Analysts are cautiously optimistic Amgen's $13.4 billion purchase of Celgene's psoriasis blockbuster Otezla will pay off.